Maternal Administration of Solithromycin, a New, Potent, Broad-Spectrum Fluoroketolide Antibiotic, Achieves Fetal and Intraamniotic Antimicrobial Protection In a Pregnant Sheep Model
Journal of Antimicrobial Agents and Chemotherapy, November 2013
One of our sponsors, Cempra Pharmaceuticals, successfully demonstrated the ability of their antibiotic, solithromycin, to cross the maternal/fetal barrier in a pregnant sheep model. BioAgilytix provided the analytical support for this study and David Johnson, Ph.D., our Director of DMPK, contributed to a paper that was published on the story in the December issue of the Journal of Antimicrobial Agents and Chemotherapy. Read this paper